[FHCO] Female Health Company (The)

Overview

Type of security: Stock

Sector: Basic Industries

Industry: Specialty Chemicals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.98 Change: -0.01 (-1.01%)
Ext. hours: Change: 0 (0%)

chart FHCO

Refresh chart

Description: The Female Health Company develops, manufactures, and markets consumer health care products. It offers the FC2 female condom that provides women dual protection against unintended pregnancy and sexually transmitted infections, including HIV/AIDS. The company sells its products to global agencies, non-government organizations, ministries of health, and other government agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It operates in South Africa, Angola, Brazil, Uganda, Nigeria, Zimbabwe, Tanzania, the United States, Brazil, Malaysia, the Democratic Republic of the Congo, and internationally. The company was founded in 1896 and is headquartered in Chicago, Illinois.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-152.96% Sales Growth - 4 Quarters 38.95% Sales Growth - Q/Q64.84% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA8.54% ROE9.87% ROI
Current Ratio4.15 Quick Ratio3.55 Long Term Debt/Equity Debt Ratio0.15
Gross Margin55.55% Operating Margin19.13% Net Profit Margin9.86% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities-130 K Cash From Operating Activities-3.04 M Gross Profit4.63 M
Net Profit1.17 M Operating Profit1.45 M Total Assets37.16 M Total Current Assets20.85 M
Total Current Liabilities4.61 M Total Debt Total Liabilities4.79 M Total Revenue7.81 M
Technical Data
High 52 week1.47 Low 52 week0.82 Last close1.26 Last change0%
RSI66 Average true range0.16 Beta0.31 Volume75.13 K
Simple moving average 20 days10.24% Simple moving average 50 days8.86% Simple moving average 200 days19.41%
Performance Data
Performance Week5% Performance Month15.6% Performance Quart23.53% Performance Half18.87%
Performance Year-14.29% Performance Year-to-date38.46% Volatility daily3.24% Volatility weekly7.24%
Volatility monthly14.83% Volatility yearly51.36% Relative Volume255.21% Average Volume77.77 K
New High New Low

News

2019-05-15 14:36:40 | Edited Transcript of FHCO earnings conference call or presentation 15-May-19 12:00pm GMT

2018-12-13 13:49:40 | Edited Transcript of FHCO earnings conference call or presentation 13-Dec-18 1:00pm GMT

2018-08-15 03:25:05 | Edited Transcript of FHCO earnings conference call or presentation 14-Aug-18 12:00pm GMT

2018-05-16 14:02:08 | Edited Transcript of FHCO earnings conference call or presentation 9-May-18 12:00pm GMT

2018-02-14 20:01:48 | Edited Transcript of FHCO earnings conference call or presentation 14-Feb-18 1:00pm GMT

2018-01-05 20:22:27 | Edited Transcript of FHCO earnings conference call or presentation 5-Jan-18 1:00pm GMT

2017-11-21 17:59:09 | At $1.1572, Is Veru Inc VERU A Buy?

2017-08-10 08:30:00 | Veru Inc. Announces Change in Nasdaq Ticker Symbol to VERU

2017-08-08 10:58:46 | Edited Transcript of FHCO earnings conference call or presentation 8-Aug-17 12:00pm GMT

2017-08-08 06:00:00 | Veru Inc. Reports Fiscal Third Quarter Financial Results

2017-08-02 08:30:00 | Following Successful Special Meeting of Stockholders, Veru Healthcare Implements Key Stockholder Proposals

2017-07-31 08:30:00 | Veru Healthcare To Report Fiscal Third Quarter 2017 Financial Results and Corporate Performance on August 8, 2017

2017-07-20 08:30:00 | Veru Healthcare Announces Key Advancements in the Development of Tamsulosin DRS for Benign Prostatic Hyperplasia

2017-07-18 16:50:00 | Significant Shareholder Demands Board Abandon Plans for Special Meeting on July 28th and Form a Special Committee to Investigate Corporate Wrongdoing

2017-06-02 08:30:00 | Veru Healthcare to Present at the 7th Annual LD Micro Invitational

2017-05-24 08:30:00 | Veru Healthcare to Advance Proprietary Drug for the Treatment of Hot Flashes in Men Receiving Prostate Cancer Hormonal Therapy Following FDA Meeting

2017-05-13 11:30:00 | Veru Healthcare Presents Results from Phase 4 Clinical Study of PREBOOST for Management of Premature Ejaculation

2017-05-12 19:21:06 | Edited Transcript of FHCO earnings conference call or presentation 9-May-17 12:00pm GMT

2017-05-12 15:56:42 | ETFs with exposure to The Female Health Co. : May 12, 2017

2017-05-11 11:51:10 | The Female Health Co. :FHCO-US: Earnings Analysis: Q2, 2017 By the Numbers : May 11, 2017

2017-05-10 08:46:01 | Edited Transcript of FHCO earnings conference call or presentation 9-May-17 12:00pm GMT

2017-05-09 07:00:00 | Investor Network: Female Health Company to Host Earnings Call

2017-05-09 06:30:00 | Veru Healthcare Reports Fiscal 2017 Second-Quarter Financial Results

2017-05-02 06:50:00 | The Female Health Company / Veru Healthcare Announces Presentation of PREBOOST® Clinical Data at American Urological Association 2017 Annual Meeting

2017-05-02 06:30:00 | The Female Health Company / Veru Healthcare to Report Fiscal 2017 Second-Quarter Financial Results, Host Conference Call on Tuesday, May 9

2017-04-26 17:20:00 | This Biotech Small-Cap Has Big Ambitions

2017-04-12 08:30:00 | The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Evaluate Bioequivalence Between Tamsulosin DRS and FLOMAX®

2017-04-11 08:30:00 | The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice President of Clinical Development

2017-04-05 16:45:30 | ETFs with exposure to The Female Health Co. : April 5, 2017

2017-03-21 16:11:02 | FEMALE HEALTH CO Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2017-03-10 12:19:27 | The Female Health Co. :FHCO-US: Earnings Analysis: Q1, 2017 By the Numbers : March 10, 2017

2017-03-09 08:30:00 | The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS with FLOMAX®

2017-03-09 08:30:00 | The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS with FLOMAX®

2017-03-03 13:06:07 | The Female Health Company / Veru Healthcare to Host Investor Conference Call on Thursday, March 9th

2017-02-16 08:30:00 | The Female Health Company / Veru Healthcare Names Matthew Gosnell, Ph.D., as Senior Vice President of Manufacturing, Preclinical and Pharmaceutical Development

2017-02-09 17:21:25 | FEMALE HEALTH CO Files SEC form 10-Q, Quarterly Report

2017-01-20 13:17:09 | ETFs with exposure to The Female Health Co. : January 20, 2017

2017-01-17 15:47:01 | FEMALE HEALTH CO Files SEC form 8-K/A, Financial Statements and Exhibits

2017-01-06 09:35:07 | The Female Health Company / Veru Healthcare Launches PREBOOST® For Premature Ejaculation

2017-01-06 08:30:00 | The Female Health Company / Veru Healthcare Launches PREBOOST® For Premature Ejaculation

2017-01-05 09:34:08 | The Female Health Company / Veru Healthcare Appoints Brian J. Groch as Chief Commercial Officer

2017-01-05 08:30:00 | The Female Health Company / Veru Healthcare Appoints Brian J. Groch as Chief Commercial Officer

2017-01-04 08:43:12 | The Female Health Company / Veru Healthcare Receives $2.8 Million Payment Toward Outstanding Receivables

2017-01-04 08:30:00 | The Female Health Company / Veru Healthcare Receives $2.8 Million Payment Toward Outstanding Receivables

2016-12-29 13:54:17 | ETFs with exposure to The Female Health Co. : December 29, 2016

2016-12-19 11:38:25 | ETFs with exposure to The Female Health Co. : December 19, 2016

2016-12-16 08:08:07 | The Female Health Co. :FHCO-US: Earnings Analysis: 2016 By the Numbers : December 16, 2016

2016-12-12 10:25:24 | FEMALE HEALTH CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2016-12-12 08:30:00 | The Female Health Company / Veru Healthcare Reports Fiscal 2016 Fourth-Quarter, Full-Year Financial Results

2016-12-08 11:19:59 | FEMALE HEALTH CO Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits